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Abstract
Virus-like particles composed of hepatitis B virus (HBV) or bacteriophage Qβ capsid proteins have
been labeled with azide- or alkyne-containing unnatural amino acids by expression in a methionine
auxotrophic strain of E. coli. The substitution does not affect the ability of the particles to self-
assemble into icosahedral structures indistinguishable from native forms. The azide and alkyne
groups were addressed by Cu(I)-catalyzed [3 + 2] cycloaddition: HBV particles were decomposed
by the formation of more than 120 triazole linkages per capsid in a location-dependent manner,
whereas Qβ suffered no such instability. The marriage of these well-known techniques of sense-
codon reassignment and bioorthogonal chemical coupling provides the capability to construct
polyvalent particles displaying a wide variety of functional groups with near-perfect control of
spacing.
INTRODUCTION
A variety of strategies and expression systems have been employed to cotranslationally
incorporate unnatural amino acids into proteins. The three most common approaches are the
use of a nonsense or rare codon (1-8), the use of a larger (quadruplet) codon (4,9), or the
reassignment of a sense codon (10-17). In the last approach, codons for methionine (11-15,
18,19), leucine (20), isoleucine (21), phenylalanine (22), tryptophan (23,24), and proline (25)
have been used for incorporation of unnatural amino acids. Here we employ this technique
(10,16,26) to replace methionine with the unnatural amino acids azidohomoalanine (1, Figure
1) and homopropargyl glycine (2) for the first time in proteins that spontaneously assemble
into virus-like particles in the host E. coli cell.
The incorporation of organic azides and terminal alkynes introduces highly energetic functional
groups that are inert to biological molecules under physiological conditions. The azide group's
“bio-orthogonality” has been particularly prized, due to its participation in the Staudinger
reaction with phosphines (27,28), cycloaddition with strained-ring alkynes (27,29-31), and
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copper(I)-mediated cycloaddition with terminal alkynes (32,33). We have developed the last
of these into a robust tool for making connections with biological molecules (34) at reasonable
concentrations (35). The process has been used by us and others for the selective modification
of enzymes (6,36), cells (14,15,37), virus particles (7,34,35,38,39), newly synthesized proteins
(40-43), and tissue lysates (44,45). The cotranslational incorporation of azides and alkynes into
self-assembled virus-like particles enables their use in the chemoselective preparation of
polyvalently labeled structures. In addition to providing near-perfect control over the
positioning of desired groups on the virus surface, the genetic incorporation and subsequent
chemical addressing of azides and alkynes allows the independent use of other bioconjugation
techniques without protecting group manipulations or concerns about cross-reactivity.
The inner protein shell (core antigen) of hepatitis B virus is composed of either 180 (maximum
diameter 318 Å) or 240 (maximum diameter 348 Å) copies of the coat protein (Figure 2) (46,
47). We will use the abbreviation HBV to refer to the latter structure, which is the predominant
(46) particle used here; the designation HBcAg also appears in the literature. The native capsid
protein is 183 amino acids in length; we employed the assembly domain composed of the first
149 amino acids (Cp149), which is largely α-helical and produces more than 95% of the 240-
subunit particle. While a variety of recombinant protein expression systems have been used
successfully to produce the HBV core antigen (48,49), by far the most common has been E.
coli (50,51).
The E. coli bacteriophage Qβ is composed of 180 copies of the coat protein assembled into a
T = 3 icosahedral virion (average diameter 270 Å, Figure 2) (52,53), encapsidating a positive-
sense RNA genome (54). The capsid protein is composed of 132 amino acids of mostly
antiparallel β-sheet structure (52,55). For a nonthermophile, the capsid is unusually stable
toward extremes of pH, temperature, and chemical reagents, due to a combination of a large
noncovalent contact area within capsid dimers. Furthermore, cysteine residues at positions 74
and 80, located at the five- and threefold axes of symmetry, respectively, form disulfide
linkages to the corresponding residues of neighboring subunits. As a result, rings of five
subunits are formed at the icosahedral fivefold symmetry axis, and rings of six protein subunits
are formed around the threefold axis, with each protein dimer being linked to the capsid by
four disulfide bonds. The coat protein of Qβ is tolerant of genetic manipulation and can be
recombinantly expressed in high yields (56-58), making it desirable for a variety of
applications. All mention below of particles or virions refer to the noninfectious, self-
assembled virus-like particles (VLPs) of either HBV or Qβ, encapsidating random cellular
RNA.
RESULTS AND DISCUSSION
Unnatural Amino Acid Incorporation
We have incorporated the unnatural amino acids azidohomoalanine (1) and
homopropargylglycine (2) into HBV and Qβ using reassignment of the methionine sense
codon, which provides global replacement of all methionines with the unnatural amino acid.
Thus, genetic engineering is usually required to place Met residues where the unnatural amino
acids are desired. The presence of N-terminal methionine, required by the translational
machinery, is variable for both HBV Cp149 and Qβ, as it is for many proteins expressed in E.
coli (60). HBV contains one additional Met at position 66, situated halfway up the side of the
four helix bundle and therefore accessible to solution-phase reactants (Figure 2A). The Qβ
sequence has no other methionines, so mutants K16 M and T93 M were generated. The former
places the new amino acid at the most exposed location of the capsid exterior, while the latter
installs Met (or its surrogate) on the interior surface in a somewhat hindered position (Figure
2C).
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For the efficient incorporation of unnatural amino acids, the protein must be expressed under
tight inducible control. Native and mutant HBV and Qβ coat protein sequences were cloned
into the pQE-60 plasmid (Qiagen) and the methionine auxotroph E. coli strain M15(pREP4)
MA was used for expression. The transformed cells were grown in minimal media
supplemented with all 20 naturally occurring amino acids. When the desired mass of cells was
achieved, methionine was removed from the media by pelleting, washing, and resuspending
the cells in minimal media containing all the natural amino acids except methionine. The cells
were incubated at 37 °C for 30−60 min to allow the bacteria to deplete their intracellular stocks
of methionine. Finally protein expression was initiated by distributing the cells in minimal
media containing the 19 natural amino acids, 1 mM isopropyl-β-D-1-thiogalactopyranoside
(IPTG), and 80 mg/L of racemic 1 or 2.
A series of control experiments established that HBV or Qβ protein was produced only when
the minimal media was supplemented by Met, 1, or 2, and only in the presence of IPTG. In
media supplemented with 1 or 2, the yield of isolated HBV or Qβ particles was approximately
20−60% of the amount of protein produced in normal media under the same induction by IPTG
(Table 1), representing some of the highest yields of unnatural amino acid-containing proteins
reported thus far (see Supporting Information).
HBV and Qβ VLPs containing 1 or 2 were indistinguishable in all physical characteristics from
the analogous particles incorporating methionine (Figure 3). In each case, ultracentrifugation
through sucrose gradients (not shown) and analysis on size-exclusion chromatography
produced sharp virus bands at the same position as native capsids. Negative-stained
transmission electron microscopy images of the particles revealed homogeneous samples of
icosahedral nonaggregated particles. (The HBV Cp149 particles containing 1 do not contain
nucleic acid, and thus exhibit stain uptake with dark centers. Qβ particles are packed full of
random cellular nucleic acid and have light centers in the negative stained images.) SDS-PAGE
analyses revealed the same high purities of the capsids containing unnatural amino acids as
those obtained with methionine. Last, the structures of both the HBV and Qβ virus-like particles
with 1 were confirmed by cryo-electron microscopy image reconstruction. The electron density
maps overlaid well with the published X-ray crystal structures for the native capsids.
The incorporation of 1 and 2 in place of methionine was confirmed by trypsin digestion and
analysis of the resulting peptides using MALDI mass spectrometry, with the results
summarized in Figure 4. Sequence coverage of the wild-type and 1-labeled HBV Cp149
particle was nearly complete, with all but two residues included (Ile97, Arg98). Following
normal expression in the presence of all 20 amino acids, Met was found at positions 1 and 66,
the former in 70−90% of the protein, varying from batch to batch. The same result was observed
when 1 was substituted for Met in the protocol described above, with 1 incorporated at the N-
terminus in 70−90% of the protein produced, and completely (>95%) at position 66. The
mutation M66S was also constructed, and found to contain the same 70−90% of 1 at the N-
terminus when expressed with the unnatural amino acid.
Analysis of Qβ capsids required shorter trypsin digestion times to ensure limited proteolysis
of the amino-terminal region. A coverage map that included all peptide fragments larger than
three amino acids was obtained (Figure 4). Post-translational processing at the N-terminus was
found to vary with the nature of the residue installed at that position. Under normal (Met-
containing) expression, Met1 was never detected in either wild-type or mutant particles,
showing that it was processed away during protein production (therefore, the amino acid
numbering eliminates this residue). When 1 was substituted for Met in any form of the Qβ
sequence, approximately 10% of the capsids were found to have the unnatural amino acid at
the N-terminus. However, in approximately one of every five batches this level of incorporation
spiked to as much as 90%. It was therefore necessary to analyze each preparation of Qβ capsids
Strable et al. Page 3













to determine the number of azide-containing residues available for conjugation. Incorporation
of 1 at either of the internal positions tested (16 or 93) was uniformly excellent (>95%). The
same type of analysis (not shown) revealed 50% incorporation of 2 into Qβ K16 M at position
16, with the remainder being Met. No homopropargyl glycine was detected at position 1.
Conjugation to Genetically Incorporated Azide and Alkyne Groups
Since the expression of HBV in the presence of 1 provided 70−90% incorporation at position
1 and complete incorporation at position 66, a maximum of approximately 410−460 azides per
VLP should be available for conjugation. We employed these particles as reagents in the
copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction, using CuOTf and
accelerating ligand 4 under inert atmosphere as has been previously described (61,62). The
purified virus was pelleted out of solution, taken into an inert-atmosphere glovebox, and
resuspended in degassed 0.1 M Tris buffer (pH 8.0) to prepare for reaction with fluorescein
alkyne 3 under our standard conditions, as shown in Figure 5. After 16 h at room temperature,
intact capsids could neither be detected by size-exclusion chromatography (Figure 6) nor
recovered from sucrose gradients. However, gel electrophoresis (Figure 6) showed strong
fluorescein labeling of the protein. Trypsin digestion and MALDI analysis in the manner
described above revealed that approximately 50% of the sites at position 66 were labeled with
fluorescein (equal intensities for the 56−81 fragment, m/z = 2919.3, and its labeled analogue
with an increase in mass of 413 Da). Interestingly, fewer than 10% of the azide groups at
position 1 were addressed.
HBV particles lacking incorporated azide groups were found to be stable toward the reaction
conditions without coupling to fluorescein, ruling out nonspecific adsorption of the dye (Table
2, entry 1). All HBV particles were stable to the CuAAC reaction conditions (copper, ligand,
buffer, and sample handling) and also toward extended incubation with fluorescein alkyne 3
in the absence of CuAAC catalyst. However, the particles did decompose when either ligand
4 or the previously used tris(triazolylmethyl)amine 5 was employed in the CuAAC process,
showing that the nature of the ligand made no difference to particle stability. When the reaction
time was varied, or the amount of catalyst was reduced, virus-like particles were recovered in
yields inversely proportional to the amount of CuAAC reaction that had occurred. The use of
rhodamine, biotin, or Gd(DOTA) reagents (6, 7, or 8) in place of fluorescein alkyne gave similar
results. We therefore conclude that the decomposition of the particle was caused by the covalent
attachment of these structures. We have previously observed other particles such as cowpea
mosaic virus (CPMV) to be similarly sensitive to the covalent tethering of flat, hydrophobic
species such ferrocene, tetramethylrhodamine, Fe(III) protoporphyrin IX, Ru(II) bipyridine
complexes, and doxorubicin. However, the nature of the attached species varied somewhat in
this case, and so it may well be that the triazole linkage, which is common to each of these
examples, is responsible for the instability of the virus-like HBV particle. CPMV and Qβ have
both been shown to be stable toward high levels of coverage by triazoles (34,35,37,38,62).
We attempted to strike a balance between covalent attachment and stability for HBV by varying
the concentrations of CuOTf, ligand 4, fluorescein-alkyne 3, and protein. The use of 250 μM
CuOTf with 500 μM ligand 4 slowed the reaction enough to allow the recovery of a maximum
of 40% of the starting amount of capsids as intact icosahedra, bearing an average of 120
fluorescein molecules per capsid (Table 2, entry 2). The vast majority of these were attached
to the M66 position and not to the N-terminal azidohomoalanine residue, as shown by trypsin
digestion/MS. The loading value was determined by UV–vis absorbance spectroscopy of
fluorescein (495 nm) in samples of purified labeled particles, with calibration using known
samples under similar conditions (fluorescein in the presence of protein; protein concentrations
determined by Lowry protein assay). It should also be noted that the attachment reaction was
inhibited by the use of ligand 4 in greater than a 2:1 molar ratio with respect to Cu, consistent
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with previous observations (61), and that higher concentrations of Cu catalyst 4 gave rise to
greater amounts of capsid decomposition as the number of reactions climbed above the 120-
per-particle level.
The site of bioconjugation was moved from the spike to the “floor” of the HBV structure by
mutation of M66 to serine. Expression of the M66S Cp149 mutant in the presence of
azidohomoalanine 1 allowed the isolation of a particle having reactive azide only at the N-
terminus (70−90% incorporation, Table 1). Reaction with fluorescein-alkyne 3 under the
conditions shown in Figure 5 gave rise to the same approximate loading of 120 per particle,
but isolated in significantly higher yield (60−70%, which represents the maximum possible
recovery at this scale due to losses in sample handling from sucrose gradient purification; Table
2, entry 3). Since the HBV particle bearing azidohomoalanine at both positions 1 and 66 showed
predominant labeling at the latter, we conclude that the more exposed position on the 4-helix
bundle is both more reactive and more deleterious to capsid stability when labeled.
Decomposition of the particle results in denaturation and precipitation, and thus removal of
protein from the labeling reaction. The greater capsid stability in the M66S case may derive
from the fact that the N-terminus, now the only site bearing azide groups, is relatively far from
the interface between subunit dimers. Compounds attached by flexible linkers to M66, in
contrast, are positioned to easily interact with the hydrophobic interior of each 4-helix bundle.
The potential for small molecules to affect HBV capsid assembly and stability by binding at
subunit interfaces has been previously illustrated for certain dihydropyrimidine derivatives
(63,64).
Qβ proved to be much more amenable to CuAAC derivatization. Each of the few azide groups
in the wild-type virus-like particle containing 1 at 5−10% of the N-terminal sites was addressed
with alkyne reagent 4 (Table 2, entry 5). When 1 was additionally installed at each of the highly
exposed K16 M positions, the particle was also completely labeled with fluorescein, causing
no apparent decomposition (Table 2, entry 6). A rare sample in which azidohomoalanine was
largely retained at the N-terminus, designated Qβ (1M-N3)160(K16M-N3)180, took on 306 ±
30 dyes under standard conditions, and 330 ± 20 dyes in the presence of higher concentrations
of protein and catalyst, all with excellent particle yield and stability (Table 2, entry 7). Loading
values were determined with calibrated measurements of fluorescein absorbance and protein
concentration determined by a modified Lowry assay, since the Qβ VLP contains no tryptophan
residues, making for poor UV–vis absorbance characteristics. The resulting particles and
protein were characterized in the same manner as HBV above (see Figure 3 for size-exclusion
chromatography and gel electrophoresis). Trypsin digestion and mass spectrometry confirmed
the loading values by showing the expected peptide fragments (and only those fragments) to
be increased by 413 Da.
The accessibility of the K16M-N3 insertion was further demonstrated by the chemoselective
conjugation of a protein to the Qβ(1M-N3)9−18(K16M-N3)180 particle. Transferrin, an 80 kD
iron transport protein, was derivatized with N-propargylbromoacetamide and purified to give
9 (Figure 5), in analogous fashion to a maleimide-alkyne derivative previously described
(35). The CuAAC reaction of 9 with Qβ (1M-N3)9−18(K16M-N3)180 gave a particle bearing
covalently attached transferrin, as shown by gel electrophoresis and TEM (Figure 6).
Qβ (1M-N3)9−18(T93M-N3)180, in which the nonterminal unnatural amino acid is on the
interior surface of the capsid, was not nearly as reactive as the K16 M derivative (Table 2, entry
8). While all of the N-terminal residues were coupled to 3 under standard CuAAC conditions,
only 30−40 dyes were attached to the particle in total, which means that only 20−30 of the 180
azide-labeled T93 M sites participated in the reaction. As before, yields of intact particles were
good. The same result was observed when alkyne 8 was used. Position 93 has both a more
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congested protein environment than position 16, and may well be occluded by associated RNA
packaged inside the particle, giving rise to sluggish reactivity.
Lastly, the alkyne-containing particle Qβ (K16M-CCH)90 proved to be sensitive to the
attachment of fluorescein azide 10 (Table 2, entry 9), giving rise to low recoveries of partially
conjugated material. Note that azide 10, and not alkyne 3, induces instability in the resulting
Qβ conjugate (each attached to unnatural amino acids installed at the same site). This is
presumably a function of the longer tether between the reactive group and the fluorescein
moiety in 10, allowing the polycyclic aromatic structure to more easily interact with
hydrophobic subunit interfaces in the particle. The use of selenomethionine derivative 11, on
the other hand, provided clean and complete triazole formation with no loss of particle integrity
(Table 2, entry 10), showing again that triazole moieties are well tolerated by the Qβ capsid.
CONCLUSIONS
We describe here the first successful site-specific incorporation and subsequent reaction of
unnatural amino acids into virus-like particles. The substitutions of azide- and alkyne-
containing structures for methionine had no apparent effect on the ability of the resulting
proteins to self-assemble into icosahedral capsids that are indistinguishable in structure from
the native forms. Tight control over protein expression in methionine auxotrophic cells resulted
in high yields of the assembled capsids. The degree of post-translational removal of unnatural
amino acid introduced in position 1 in place of Met was variable, and was characterized by
trypsin digestion and mass spectrometry analysis.
These novel capsids can be chemically addressed with perfect chemoselectivity by the CuAAC
reaction. HBV was found to be sensitive to the coupling of molecules to the 4-helix-bundle
spikes, while Qβ suffered from much fewer limitations in this regard. The low concentrations
of azide and alkyne reagents required for coverage of most or all of the inserted azide and
alkyne groups are made possible by the efficiency of the CuAAC process. Because the CuAAC
reaction is insensitive to the substituents present on the azide and alkyne reactants and similarly
unreactive with natural protein functional groups, the two-step process of genetically directed
incorporation of azides or alkynes followed by CuAAC ligation provides a functional
equivalent to the installation of almost any unnatural (triazole-linked) amino acid one can
imagine.
EXPERIMENTAL PROCEDURES
CP149 HBV Plasmid Construction
A pET11c plasmid containing the Cp149 sequence was gratefully received from Prof. Adam
Zlotnick of the Oklahoma University Health Sciences Center. In order to provide tight inducible
control overexpression (pET11c was found to be constitutively expressed to an unacceptable
degree), the HBV gene was amplified using the following primers: Cp149F 5′-AAG AAG
GAG GAT ATA GGT CTC AC ATG GAC ATT GAC CCT-3′ and Cp149R 5′-TCG GGC
TTT GTT AGC AGC CGG AAG CTT ATA CTA AAC AAC CGT-3′ The PCR product was
sequentially digested with Hind III and Bsa I, and then ligated into pQE-60 plasmid (Qiagen)
which had been sequentially digested with Hind III and Nco I. The resulting plasmid was
transformed into competent M15MA cells harboring the pREP4 plasmid yielding the
expression cells M15MA(pQE-60/HBV).
Site-Directed Mutagenesis of Cp149 HBV
Mutations were introduced into the coat protein of HBV by standard overlap PCR to remove
the methionine at position 66 (M66S). The following general forward and reverse primers were
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used: Forward 5′-AGA ATT CAT TAA AGA GGA GAA ATT AAC-3′, Reverse 5′-CCA AGC
TCA GCT AAT GCT TAT CCT-3′, M66SF 5′-GGA GAC TTA TCT ACT CTA GCT-3′,
M66SR 5′-AGC TAG AGT AGA TAA GTC TCC-3′. The PCR products were sequentially
digested with Hind III and NcoI and ligated into pQE-60 that had previously been digested
with Hind III and Nco I. The resulting plasmids were transformed into competent M15MA
cells yielding the following expression construct: M15MA(pQE-60/M66S HBV).
Insertion of the K16 M Qβ Coat Protein Gene into pQE-60
The coat protein gene for Qβ containing the point mutation K16 M was originally created in
the pET-28b plasmid, which is not compatible with expression in M15 based Met auxotrophic
E. coli cells. Therefore, the Qβ coat protein gene was amplified from the pET-28b plasmid
using the following primers: QBF 5′-AAA GAG GAG AAA TTA AGG TCT CAC ATG GCA
AAA TTA GAG ACT-3′ and QBR 5′-CCA AGC TCA GCT AAT TAA GCT TTA TTA
ATA-3′ The PCR product was sequentially digested with Hind III and Bsa I. The digested PCR
product was ligated into pQE-60 plasmid (Qiagen), which had been sequentially digested with
Hind III and Nco I. The resulting plasmid was transformed into competent M15MA cells
harboring the pREP4 plasmid yielding the expression cells M15MA(pQE-60/Qβ K16M).
Site-Directed Mutagenesis of K16 M Qβ
The following primers were used to introduce Met at position 93 (T93M), using standard
overlap PCR as above: Forward 5′-AGA ATT CAT TAA AGA GGA GAA ATT AAC-3′,
Reverse 5′-CCA AGC TCA GCT AAT GCT TAT CCT-3′, WTF 5′-GGA GAC TTA TCT
ACT CTA GCT-3′, WTR 5′-AGC TAG AGT AGA TAA GTC TCC-3′. The PCR products
were sequentially digested with Hind III and NcoI and ligated into pQE-60 that had previously
been digested with Hind III and Nco I. The resulting plasmids were transformed into competent
M15MA cells yielding the following expression construct: M15MA(pQE-60/WT Qβ) and
M15MA(pQE-60/T93 M Qβ).
Synthesis of Unnatural Amino Acids (1 and 2)
Several short routes to azidohomoalanine (1) have been reported in the literature (15,65-67).
We chose a simplified version of the method of Rappoport and co-workers (68), since the
starting lactone is commercially available in racemic form at modest cost and an enantiospecific
synthesis is not required because E. coli incorporates only the L-isomer during protein
expression. α-Amino-γ-butyrolactone hydrobromide (5.02 g, 27.6 mmol) was refluxed in 1:1
HBr/glacial HOAc (250 mL) overnight (17−24 h). The HBr and acetic acid were then removed
by rotary evaporation, yielding crude bromohomoalanine. The crude material was then
dissolved in a solution of NaN3 (9.00 g, 138 mmol) in water (125 mL) and refluxed again
overnight. The solution was evaporated to dryness and the residual tan solid resuspended in a
minimal volume of 0.1 M HCl. The acidic solution was passed through a column of Dowex
50WX4−100 ion-exchange resin, washing with water and eluting the product with 1 M
NH4OH. The collected fractions were evaporated to dryness, yielding an oil. Compound 1 was
obtained as a tan solid (1.49 g, 10.3 mmol, 37%) upon resuspending in a minimal volume of
water and lyophilizing. The purity of the solid was determined by NMR using pyridine as an
internal standard and generally was >85% (overall yields 32−38%). 1H NMR (D2O, 200 MHz,
d1 = 10 s) δ 3.44 (t, 2H, CHCH2CH2N3), 3.07 (dd, 1H, CHCH2CH2N3), 1.58 (m, 2H,
CHCH2CH2N3). Homopropargylglycine (2) was prepared as previously described (10).
Incorporation of 1 into HBV and Qβ
A single of colony of cells expressing the desired HBV or Qβ construct was used to inoculate
5 mL of SOB media containing carbenicillin (100 μg/mL) and kanamycin (50 μg/mL) and was
grown overnight. The resulting culture was transferred into 500 mL of M9 minimal media
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supplemented with all 20 amino acids, carbenicillin (100 μg/mL), and kanamycin (100 μg/mL)
and allowed to grow for 8 h. Aliquots (25 mL) of the resulting culture were transferred into
each of 11 flasks containing 500 mL of fresh minimal media supplemented with all 20 amino
acids, carbenicillin (100 μg/mL) and kanamycin (100 μg/mL) and allowed to grow overnight.
In the morning the cells were pelleted and resuspended in 500 mL of fresh M9 minimal media
supplemented with all of the natural amino acids minus methionine. The cells were agitated at
37 °C for 30−40 min, and then transferred into new flasks of M9 minimal media supplemented
with all of the natural amino acids minus methionine, IPTG (1 mM), carbenicillin (100 μg/
mL), kanamycin (100 μg/mL), and azidohomoalanine (80 mg of racemate). After 6 h at 37 °
C, the cells were harvested and stored at −80 °C.
For each preparation, 30−60 g of cells were allowed to thaw at room temperature and were
resuspended in 50 mL distilled water. Cold lysis buffer (200 mL, 50 mM HEPES pH 8.0, 500
mM NaCl, 0.1 mg/mL DNase1, and 0.1 mg/mL RNaseA) was added and the cells were
subjected to three cycles of sonication (2 min sonication and 2 min rest per cycle). Lysozyme
(1 mg per mL of lysis buffer) was added and the solution was stirred in the cold room for 1 h.
Insoluble cell debris was removed by centrifugation at 10 000 rpm for 30 min in a JA-10 rotor
(Beckman).
For HBV, ammonium sulfate was added to the supernatant to a final concentration of 40% of
saturation, and allowed to stir at room temperature for 30 min. The precipitated HBV coat
protein was separated by centrifugation (10 000 rpm, 30 min, JA-10 rotor), and then was
resuspended in 0.1 M potassium phosphate buffer (50 mL, pH 7.0). Any remaining insoluble
material was removed by centrifugation (10 000 rpm, 15 min, JA-17 rotor). Sodium chloride
was added to a final concentration of 0.5 M and the HBV coat proteins were allowed to assemble
overnight. The resulting assembled VLPs were separated from smaller proteins by
ultrapelleting (42 000 rpm, 6 h, 4 °C, 50.2Ti rotor, L90K ultracentrifuge). The pelleted material
was resus-pended in 3−10 mL of 0.1 M potassium phosphate buffer (pH 7.0). Further
purification was accomplished by the use of two successive sucrose gradient sedimentations
(10−40% sucrose gradients in SW28 rotor at 28 000 rpm for 6 h at 4 °C.
For Qβ, PEG 8000 was added to the supernatant to a final concentration of 10% and the mixture
was allowed to stir at room temperature for 30 min. The precipitated Qβ capsids were separated
by centrifugation (10 000 rpm, 30 min, JA-10 rotor), and then resuspended in 0.1 M potassium
phosphate buffer (50 mL, pH 7.0). Insoluble material was removed by centrifugation (10 000
rpm, 15 min, JA-17 rotor), and VLPs were isolated and purified as for HBV above, with final
concentration by ultrapelleting.
Characterization of HBV and Qβ Particles
All protein preparations were analyzed by denaturing gel electrophoresis (4−12% NuPAGE
Bis-Tris gel, Invitrogen) to estimate their purity; in all cases, the anticipated coat protein band
constituted >95% of the intensity visualized by densitometry after Coomassie blue staining.
HBV concentration was determined by absorbance at 280 nm, 1 mg/mL providing an
absorbance value of 1.74. The concentrations of modified HBV and all Qβ particles were
determined with the Modified Bradford Assay (Pierce, Inc.) and a BSA standard curve. Since
HBV VLPs do not contain significant quantities of RNA, the ratio of absorbances at 260 nm
vs 280 nm was 0.6−0.7. Qβ VLPs package random cellular nucleic acid, giving rise to A260/
A280 values of 1.8−1.9. The presence of individual, aggregated, and disassembled particles was
determined by size-exclusion chromatography on a Superose 6 column using an Akta Explorer
(GE Healthcare) fast protein liquid chromatography (FPLC) instrument. Transmission electron
microscopy was performed by applying particles at a concentration of 0.2 mg/mL to a carbon-
coated Formvar transmission electron grid. The grids were stained with 2% uranyl acetate, and
visualized in a Phillips CM120 transmission electron microscope.
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VLP samples were processed for determination of derivatization site(s) by MALDI mass
spectrometry as follows. Samples (100 μL, 1−2 mg/mL protein) were mixed with 300 μL of 8
M urea and 30 μL of 1 M DTT, and incubated at 37 °C for 1 h to allow the protein to denature.
Iodoacetamide (1 M, 50 μL) was added to cap any free cysteines and the sample was again
incubated at 37 °C for 1 h. DTT (30 μL) was added to quench unreacted capping reagent, and
the samples were diluted to a final volume of 1.9 mL using 25 mM ammonium bicarbonate
(pH 8.0). Each sample was digested with 30 μg of either trypsin or Glu-C protease overnight
at 37 °C. The samples were then concentrated to approximately 300 μL, and urea was removed
with Zip-tips (Microcon) prior to MALDI analysis.
Cryoelectron Microscopy and Analysis
Samples were prepared for CryoEM analysis by preservation in vitreous ice via rapid-freeze
plunging onto plasma cleaned Cflat carbon film grids using a Vitrobot (FEI Co). Data collection
was performed on Tecnai F20 electron microscopes (FEI Co.) operating at 120 keV using a
dose of ∼20e−/Å2 and a nominal underfocus of 0.8 to 3 μm utilizing the Leginon data collection
software (69). For the reconstructions, 735 micrographs of azidohomoalanine-incorporated
HBV were collected at a nominal magnification of 80 000× at a pixel size of 0.14 nm at the
specimen. 125 micrographs of azidohomoalanine-incorporated Qβ particles were collected at
a nominal magnification of 50 000× at a pixel size of 0.23 nm at the specimen. All micrographs
were collected on a 4000 × 4000 CCD camera (Gatan Inc.). CryoEM analysis of all other Qβ
variants, including the transferrin-alkyne conjugated particles, was performed under the same
conditions as the azidohomoalanine-incorporated HBV particles.
The contrast transfer function (CTF) for each micrograph was estimated using the Automated
CTF Estimation (ACE) package (70). 8906 HBV particles and 11 882 Qβ particles were
extracted from the collected data at a box size of 304 × 304 pixels and 180 × 180 pixels,
respectively. The HBV particles were binned by a factor of 2 for the reconstruction. Phase
correction of the single particles and subsequent three-dimensional refinement was carried out
with the EMAN software package (71). The amplitudes of the resulting refined structures were
adjusted with the SPIDER software package (72). Resolution of the final HBV and Qβ densities
were determined to be around 8 Å and 10 Å (respectively) according to 0.5 FSC criteria. Rigid-
body docking of crystal structures into the reconstruction density and graphical representations
were produced by the Chimera visualization software package (73,74).
Copper Catalyzed Azide-Alkyne Cycloaddition Reactions
Purified azide-containing HBV or Qβ particles were pelleted out of solution (42 000 rpm, 6
h), the supernatant was removed, and residual buffer was allowed to drain away from the pellet.
The viral pellet was then taken into a nitrogen-filled glovebox (without exposure to vacuum)
and resuspended in a minimal volume of degassed 0.1 M Tris at pH 8.0. A small aliquot of the
virus solution was removed from the glovebox and used to determine virus concentration. A
typical conjugation reaction employed a VLP concentration of 2 mg/mL in 0.1 M Tris (pH 8.0)
in a round-bottomed 2 mL Eppendorf tube (rather than conical tubes that do not provide good
mixing upon gentle agitation). Fluorescein alkyne 6 (final concentration 1 mM) was added,
followed by a freshly prepared buffer solution of Cu(I) triflate and 2 equiv of ligand 4 or 5.
Final concentrations of Cu were either 100 μM or 250 μM for HBV, 500 μM or 1 mM for
Qβ. The tube was sealed, placed in a secondary sealed container (usually a small round-
bottomed flask), removed from the glovebox, and attached to a slow tumbler arm for agitation
at room temperature for 16−18 h. After completion of the reaction, intact virus-like particles
were separated from excess labeling reagent using a combination of 10−40% sucrose gradients
(38 000 rpm, SW41 rotor, 4 h for HBV, 3 h for Qβ) and ultrapelleting.
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Methionine analogues 1 and 2 incorporated into virus-like capsids using codon reassignment.
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HBV and Qβ virus-like particles. (A) HBV dimer; (B) HBV virus-like particle; (C) Qβ dimer;
(D) Qβ virus-like particle (47,55,59). Representations (A) and (C) look obliquely down onto
the outside capsid surface, showing the 4-helix bundle for HBV and intertwined α-helix and
loop segments over adjacent β-sheets for Qβ. The spheres mark the locations of methionine
residues: green = N-termini, white = Met66 in HBV and K16 M in Qβ, purple = Qβ T93M.
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Characterization of the HBV (A-C) and Qβ (D-F) capsids containing 1. (A and D) Size
exclusion chromatography (Superose-6), with retention times matching those of intact native
capsids. (B and E) Cryo-electron microscopy image reconstructions. (C and F) X-ray crystal
structures docked into the cryo electron density maps. Characterization data for Qβ
incorporating 2 may be found in Supporting Information.
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Summary of results from trypsin digestion and mass spectrometry of HBV and Qβ expressed
with Met and 1 in locations marked in red. The detected fragments are indicated by the
numerical values of m/z shown at the right of each; values in red are those with the unnatural
amino acid incorporated. Many fused fragments (fragments derived from incomplete cleavage)
were detected as well, giving rise to the same conclusions. The small peptides marked in gray
were not detected. Conclusions about the level of incorporation of 1 at each indicated position
are shown in the red ovals.
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Copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction of virus-like particles with
alkyne or azide derivatives.
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Characterization of virus-like capsids after CuAAC reactions: HBV = A-C; Qβ = D-H. (A)
Size exclusion chromatography showing a peak with a retention volume of 18 mL
corresponding to disassembled capsid. (B,C) SDS-PAGE of the Cp149 protein isolated from
the reaction, visualized under ultraviolet illumination (B) and then with Coumassie staining
(C). The right lane is a molecular weight ladder. (D) Size exclusion chromatography showing
an elution volume of 14 mL, characteristic of intact Qβ capsids, and coelution of fluorescein
with the protein showing covalent attachment. (E,F) SDS-PAGE of the Qβ protein showing
fluorescein labeling as above. (G) Same as (F). (H) SDS-PAGE of purified Qβ-transferrin
conjugate; the higher molecular weight bands are in the expected position for the Cp149-
transferrin fusion, with multiple bands deriving from the somewhat impure nature of the
starting transferrin sample. (I) Transmission electron microscopy (TEM) image of Qβ
(1MN3)9−18(K16M-N3)180. (J) TEM image of the same particle conjugated to transferrin-
alkyne 9, after purification. Note the appearance of spots surrounding most of the particles,
due to the tethered 80 kD protein.
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Table 1
Average Expression Levels of HBV and Qβ VLPs with Methionine, Azidohomoalanine (1), or Homopropargylglycine
(2)
particlea amino acid yield (mg protein per g
cells)
yield (mg protein per L
culture)
HBV Met 4−5 mg/g 80−100 mg/L
HBV(1M-N3)192(66M-N3)240 1 1−1.5 mg/g 20−30 mg/L
HBV(M66S) Met 4−5 mg/g 80−100 mg/L
HBV(1M-N3)102(M66S) 1 2−3 mg/g 40−60 mg/L
Qβ Met 3−4 mg/g 75−100 mg/L
Qβ(1M-N3)9−18 1 2−2.4 mg/g 50−60 mg/L
Qβ(K16M) Met 3−4 mg/g 50−75 mg/L
Qβ(1M-N3)9−18(K16M-N3)180 1 1−2 mg/g 25−35 mg/L
Qβ(K16M-CCH)90 2 2 mg/g 40 mg/L
Qβ(T93M) Met 3−4 mg/g 50−75 mg/L
Qβ(1M-N3)9−18(T93M-N3)180 1 1−2 mg/g 25−35 mg/L
a
Nomenclature: “HBV(1M-N3)(66M-N3)” denotes HBV particles with methionines at positions 1 and 66 (which happens to be the wild-type sequence)
expressed in the presence of 1 to allow azide incorporation at those residues. Other particles are designated in analogous fashion, with "CCH" replacing
"N3" for those VLP's incorporating alkynyl amino acid 2. Subscripts refer to the average number of unnatural amino acids incorporated at each position,
as described in the text.
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Table 2
Results of CuAAC Reactions of VLP's Containing Unnatural Amino Acids, as Shown in Figure 5
entry particlea # incorporated per
particleb
loadingc recoveryd
1 HBV(66M) none 0 60−70%
2 HBV(1M-N3)170−215(66M-N3)240 410−455 120 ± 15e ≤40%
3 HBV(1M-N3)170−215(M66S) 170−215 120 ± 25 60−70%
4 Qβ(K16M) none 0 75−80%
5 Qβ(1M-N3)9−18 9−18 15 ± 3 80−85%
6 Qβ(1M-N3)9−18(K16M-N3)180 189−198 190 ± 20 75−80%
7 Qβ(1M-N3)160(K16M-N3)180 340 306 ± 30f 70−80%
8 Qβ(1M-N3)9−18(T93M-N3)180 189−198 35 ± 5 75−80%
9 Qβ(K16M-CCH)90 90 50 ± 5 20%
10 Qβ(K16M-CCH)90 90 85 ± 5g 75−80%
a
See caption to Table 1 for nomenclature.
b
Total number of unnatural amino acids per particle, determined by trypsin digestion and mass spectrometry as described in the text.
c
The number of attached molecules (subscripts “m” in Figure 5). Unless otherwise indicated, the value was obtained from reaction with fluorescein
reagents 3 or 10 and quantitation by calibrated UV–visible absorbance of the dye (average of at least three independent reactions).
d
Amount of purified intact capsids recovered from the reaction.
e
More than 90% of the attachments were made at position 66.
f
Under standard conditions; a loading of 330 ± 20 (75% recovery) was observed under the most forcing conditions tested.
g
Reaction with azide 11, loading determined by quantitation of attached Se atoms by inductively coupled plasma optical emission spectroscopy.
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